• Verbascoside (SKU B3379): Reliable PKC/NF-κB Inhibition in C

  2026-05-09

  This article addresses key laboratory challenges in cell viability and osteoclastogenesis research, showing how Verbascoside (SKU B3379) from APExBIO delivers reproducible PKC/NF-κB inhibition. Evidence-based scenarios guide assay optimization, data interpretation, and vendor selection, with direct links to product specifications and the latest mechanistic literature.

• Peroxynitrite-Induced Necroptosis in Cardiac Microvascular I

  2026-05-08

  Liu et al. elucidate how hyperhomocysteinemia exacerbates cardiac microvascular ischemia–reperfusion injury (IRI) via peroxynitrite-driven ER stress and dysregulated Ca2+ flux, culminating in mitochondrial overload and necroptosis. The study identifies IP3R-mediated Ca2+ transfer as a tractable target and informs future necroptosis assay development for cardiovascular and translational research.

• BAPTA Calcium Chelator: Applied Workflows in Cell Signaling

  2026-05-08

  BAPTA enables precise calcium signaling modulation in apoptosis and cell signaling research, offering reproducibility and mechanistic clarity where traditional chelators fall short. Recent toxicology breakthroughs validate its indispensability for dissecting environmental co-exposure mechanisms in intestinal cells.

• Tolazoline in β-Cell Electrophysiology: Beyond Receptor Anta

  2026-05-07

  Explore Tolazoline’s dual role as an α2-adrenergic receptor antagonist and ATP-sensitive potassium channel blocker, with a unique focus on quantitative electrophysiological insights in β-cell research. Discover evidence-based guidance and advanced assay strategies unavailable in standard protocol articles.

• NU7441 (KU-57788): Precision DNA-PK Inhibition in Oncology R

  2026-05-07

  NU7441 (KU-57788) empowers oncology and DNA repair research with ultra-selective, nanomolar DNA-PK inhibition, enabling sensitive dissection of DNA damage response and immune escape mechanisms. Discover evidence-backed workflows, troubleshooting strategies, and advanced applications informed by recent breakthroughs in gastric cancer immunotherapy.

• A Drug-Sensitized Yeast Platform for Sensitive mTOR Inhibito

  2026-05-06

  This study presents a refined yeast-based assay system for identifying mTOR inhibitors with high sensitivity, leveraging genetic modifications to enhance responsiveness to known and novel compounds. The findings clarify the mechanistic selectivity of several metabolic agents, including canagliflozin, and provide a practical tool for drug screening in aging and cancer research.

• Verbascoside: Applied Strategies for PKC/NF-κB Inhibitor Wor

  2026-05-06

  Verbascoside stands out as a robust PKC/NF-κB inhibitor, empowering researchers to dissect osteoclastogenesis, neuroinflammation, and pain signaling with reproducible precision. Discover streamlined experimental protocols, comparative insights, and troubleshooting tips that maximize the translational value of this small molecule in bone and neuroinflammatory research.

• (-)-Norepinephrine (+)-bitartrate: Precision Tool for Cardio

  2026-05-05

  (-)-Norepinephrine (+)-bitartrate stands out as a high-potency, receptor-selective agonist for cardiovascular and adrenergic signaling studies. This guide demystifies its workflow integration, troubleshooting, and the translational impact of recent clinical research, empowering labs to achieve reproducible, clinically relevant results.

• Merimepodib (VX-497) in Antiviral and Immunosuppressive Rese

  2026-05-05

  Merimepodib (VX-497) offers researchers a precise, reversible tool to probe and manipulate guanine nucleotide biosynthesis, enabling robust workflows in antiviral, cancer, and immunology studies. This guide translates recent mechanistic breakthroughs into actionable protocols and troubleshooting, highlighting Merimepodib’s unique cross-domain advantages and APExBIO’s role as a trusted supplier.

• HDAC3-Mediated TPM3 De-2-Hydroxyisobutyrylation Drives Vasoc

  2026-05-04

  This study by Pang et al. uncovers how HDAC3 regulates abnormal vasoconstriction by modulating 2-hydroxyisobutyrylation of tropomyosin 3 at Lys141 in vascular smooth muscle cells. The findings highlight a novel epigenetic mechanism linking posttranslational modification to vascular dysfunction, suggesting new therapeutic avenues for hypertension.

• Lactate-Driven Ran Lactylation Regulates Astrocyte Polarizat

  2026-05-04

  A recent study reveals that lactate accumulation after spinal cord injury promotes astrocyte polarization via SIRT1-regulated lactylation of the Ran GTPase at lysine 123. This mechanism enhances STAT3 nuclear transport, providing new insight into metabolic-epigenetic crosstalk in CNS injury repair and potential research targets for neuroregeneration.

• Proteoform-Specific Drug Interactions in Native Cell Signali

  2026-05-03

  This study pioneers the direct profiling of proteoform-specific ligand interactions in native membrane environments, illuminating how post-translational modifications modulate drug binding and signaling. The findings advance our understanding of off-target effects, particularly of PDE5 inhibitors like Vardenafil, and set new standards for the mechanistic study of membrane protein pharmacology.

• Liproxstatin-1 HCl: Mechanistic Insights and Assay Best Prac

  2026-05-02

  Discover the advanced mechanistic basis of Liproxstatin-1 HCl in ferroptosis inhibition, with a focus on mitochondrial calcium signaling and optimized assay protocols. Uncover how this research compound uniquely informs experimental design for regulated cell death studies.

• FPH1 (BRD-6125): Optimizing Hepatocyte Proliferation Assays

  2026-05-01

  FPH1 (BRD-6125) enables robust, reproducible expansion of functional human hepatocytes, independent of donor variability—crucial for both drug screening and iPS cell differentiation workflows. This guide delivers actionable protocols, troubleshooting, and data-driven enhancements for primary hepatocyte and iHeps culture, bridging foundational research with applied cell therapy and screening solutions.

• Nicotine Signaling Accelerates CKD Progression: Mechanistic

  2026-05-01

  This article reviews recent findings on the role of nicotine signaling in the worsening of chronic kidney disease (CKD) among smokers. Focusing on activation of renal nicotinic acetylcholine receptors and downstream oxidative and fibrotic pathways, the study illuminates critical mechanisms underlying tobacco-induced kidney injury and identifies emerging targets for intervention.

15227 records 1/1016 page Next 12345 下5页 Last page